Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10466253 | 0.89 | ROCK2 (0.55) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL15145661 | 0.86 | PPID (0.60) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL10467196 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL7146192 | 0.85 | RAB9A (0.60) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL6880276 | 0.84 | ROCK2 (0.65) | L3MBTL1ROCK2ROCK1 | |
| SCHEMBL354643 | 0.84 | L3MBTL1 (0.59) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL18595010 | 0.83 | ROCK2 (0.59) | SMN1; SMN2RAB9ANPC1GAAROCK2 | |
| SCHEMBL4875670 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL6316630 | 0.82 | ROCK2 (0.62) | NAMPTROCK2ROCK1 | |
| Urea SCHEMBL4725120 | 0.81 | L3MBTL1 (0.56) | SMN1; SMN2RAB9ANPC1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2806899-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | SMN1; SMN2 3186/4885RAB9A 1440/4885NPC1 987/4885 |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | SMN1; SMN2 1571/4885RAB9A 1131/4885NPC1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.